ANAB Quote, Financials, Valuation and Earnings

Design Therapeutics has a net margin of -50.53% compared to AnaptysBio's net margin of --. AnaptysBio's return on equity of -241.25% beat Design Therapeutics's return on equity of --.

AnaptysBio has a consensus price target of $37.64, signalling upside risk potential of 81.82%. On the other hand Design Therapeutics has an analysts' consensus of $7.33 which suggests that it could grow by 89%. Given that Design Therapeutics has higher upside potential than AnaptysBio, analysts believe Design Therapeutics is more attractive than AnaptysBio.

AnaptysBio has a beta of -0.095, which suggesting that the stock is 109.47% less volatile than S&P 500. In comparison Design Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

AnaptysBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Design Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio pays -- of its earnings as a dividend. Design Therapeutics pays out -- of its earnings as a dividend.

AnaptysBio quarterly revenues are $43.1M, which are larger than Design Therapeutics quarterly revenues of --. AnaptysBio's net income of -$21.8M is lower than Design Therapeutics's net income of -$13.7M. Notably, AnaptysBio's price-to-earnings ratio is -- while Design Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio is 6.44x versus -- for Design Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Inspire Medical Systems has a net margin of -50.53% compared to AnaptysBio's net margin of 14.69%. AnaptysBio's return on equity of -241.25% beat Inspire Medical Systems's return on equity of 8.4%.

AnaptysBio has a consensus price target of $37.64, signalling upside risk potential of 81.82%. On the other hand Inspire Medical Systems has an analysts' consensus of $220.64 which suggests that it could grow by 38.71%. Given that AnaptysBio has higher upside potential than Inspire Medical Systems, analysts believe AnaptysBio is more attractive than Inspire Medical Systems.

AnaptysBio has a beta of -0.095, which suggesting that the stock is 109.47% less volatile than S&P 500. In comparison Inspire Medical Systems has a beta of 1.390, suggesting its more volatile than the S&P 500 by 38.99%.

AnaptysBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inspire Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio pays -- of its earnings as a dividend. Inspire Medical Systems pays out -- of its earnings as a dividend.

AnaptysBio quarterly revenues are $43.1M, which are smaller than Inspire Medical Systems quarterly revenues of $239.7M. AnaptysBio's net income of -$21.8M is lower than Inspire Medical Systems's net income of $35.2M. Notably, AnaptysBio's price-to-earnings ratio is -- while Inspire Medical Systems's PE ratio is 91.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio is 6.44x versus 6.00x for Inspire Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of -50.53% compared to AnaptysBio's net margin of -9.24%. AnaptysBio's return on equity of -241.25% beat Vanda Pharmaceuticals's return on equity of -3.49%.

AnaptysBio has a consensus price target of $37.64, signalling upside risk potential of 81.82%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 198.04%. Given that Vanda Pharmaceuticals has higher upside potential than AnaptysBio, analysts believe Vanda Pharmaceuticals is more attractive than AnaptysBio.

AnaptysBio has a beta of -0.095, which suggesting that the stock is 109.47% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.720, suggesting its less volatile than the S&P 500 by 28.044%.

AnaptysBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

AnaptysBio quarterly revenues are $43.1M, which are smaller than Vanda Pharmaceuticals quarterly revenues of $53.2M. AnaptysBio's net income of -$21.8M is lower than Vanda Pharmaceuticals's net income of -$4.9M. Notably, AnaptysBio's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio is 6.44x versus 1.24x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Xeris Biopharma Holdings has a net margin of -50.53% compared to AnaptysBio's net margin of -8.51%. AnaptysBio's return on equity of -241.25% beat Xeris Biopharma Holdings's return on equity of -1019.2%.

AnaptysBio has a consensus price target of $37.64, signalling upside risk potential of 81.82%. On the other hand Xeris Biopharma Holdings has an analysts' consensus of $6.08 which suggests that it could grow by 45.01%. Given that AnaptysBio has higher upside potential than Xeris Biopharma Holdings, analysts believe AnaptysBio is more attractive than Xeris Biopharma Holdings.

AnaptysBio has a beta of -0.095, which suggesting that the stock is 109.47% less volatile than S&P 500. In comparison Xeris Biopharma Holdings has a beta of 1.094, suggesting its more volatile than the S&P 500 by 9.436%.

AnaptysBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xeris Biopharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio pays -- of its earnings as a dividend. Xeris Biopharma Holdings pays out -- of its earnings as a dividend.

AnaptysBio quarterly revenues are $43.1M, which are smaller than Xeris Biopharma Holdings quarterly revenues of $60.1M. AnaptysBio's net income of -$21.8M is lower than Xeris Biopharma Holdings's net income of -$5.1M. Notably, AnaptysBio's price-to-earnings ratio is -- while Xeris Biopharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio is 6.44x versus 3.12x for Xeris Biopharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.